Compare Stocks → Urgent alert: open this for a huge profit potential (From Timothy Sykes) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:APOPNASDAQ:AVGRNASDAQ:NVIVNASDAQ:SINT Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPOPCellect Biotechnology$13.17+0.4%$11.51$6.64▼$35.52$12.87M1.87479,845 shs17,400 shsAVGRAvinger$3.98+1.5%$3.37$2.50▼$18.00$6.33M1.2647,814 shs3,597 shsNVIVInVivo Therapeutics$0.58$0.22▼$2.40$997K0.658.25 million shs1.89 million shsSINTSintx Technologies$0.05+13.8%$0.10$0.02▼$2.13$1.03M1.4621.08 million shs85.70 million shs10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPOPCellect Biotechnology0.00%0.00%0.00%0.00%0.00%AVGRAvinger+5.95%-7.11%+26.45%+42.03%-49.84%NVIVInVivo Therapeutics0.00%0.00%0.00%-56.07%-76.93%SINTSintx Technologies+7.24%+60.64%-69.23%-86.48%-98.09%Biden’s $374B Giveaway Into This Sector (Ad)Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereClick here for the full storyMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPOPCellect BiotechnologyN/AN/AN/AN/AN/AN/AN/AN/AAVGRAvinger2.1858 of 5 stars3.55.00.00.01.90.00.6NVIVInVivo TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ASINTSintx TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPOPCellect BiotechnologyN/AN/AN/AN/AAVGRAvinger3.00Buy$5.0025.63% UpsideNVIVInVivo TherapeuticsN/AN/AN/AN/ASINTSintx Technologies2.00HoldN/AN/ACurrent Analyst RatingsLatest SINT, AVGR, APOP, and NVIV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/21/2024AVGRAvingerHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.002/5/2024SINTSintx TechnologiesMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPOPCellect BiotechnologyN/AN/AN/AN/A$4.77 per shareN/AAVGRAvinger$7.65M0.83N/AN/A($4.53) per share-0.88NVIVInVivo TherapeuticsN/AN/AN/AN/A$6.48 per shareN/ASINTSintx Technologies$2.63M0.39N/AN/A$1.65 per share0.03Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPOPCellect Biotechnology-$5.62MN/A0.00∞N/AN/AN/AN/AN/AAVGRAvinger-$18.32M-$26.34N/AN/AN/A-239.41%N/A-106.16%5/8/2024 (Estimated)NVIVInVivo Therapeutics-$10.49MN/A0.00N/AN/AN/A-75.04%-65.01%N/ASINTSintx Technologies-$8.26M-$3.42N/A∞N/A-314.39%-67.12%-45.49%5/20/2024 (Estimated)Latest SINT, AVGR, APOP, and NVIV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/27/2024Q4 2023SINTSintx TechnologiesN/A-$0.09-$0.09-$0.09N/A$0.90 million3/20/2024Q4 2023AVGRAvinger$0.64-$3.93-$4.57-$3.93$2.52 million$1.91 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPOPCellect BiotechnologyN/AN/AN/AN/AN/AAVGRAvingerN/AN/AN/AN/AN/ANVIVInVivo TherapeuticsN/AN/AN/AN/AN/ASINTSintx TechnologiesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPOPCellect BiotechnologyN/A3.013.01AVGRAvingerN/A0.630.36NVIVInVivo TherapeuticsN/A14.3014.30SINTSintx TechnologiesN/A1.901.60OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPOPCellect Biotechnology4.84%AVGRAvinger18.30%NVIVInVivo Therapeutics13.78%SINTSintx Technologies18.38%Insider OwnershipCompanyInsider OwnershipAPOPCellect BiotechnologyN/AAVGRAvinger4.29%NVIVInVivo Therapeutics2.45%SINTSintx Technologies1.00%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAPOPCellect Biotechnology2,020977,000N/ANot OptionableAVGRAvinger681.59 million1.52 millionNot OptionableNVIVInVivo Therapeutics63.11 million3.03 millionNot OptionableSINTSintx Technologies4122.68 million22.45 millionNot OptionableSINT, AVGR, APOP, and NVIV HeadlinesSourceHeadlineWhy SINTX Technologies Stock Is Getting Hammeredmsn.com - April 3 at 2:48 PMSINTX Technologies Announces Pricing of $1.5 Million Public Offering of Common Stockglobenewswire.com - April 3 at 9:00 AMWhy SINTX Technologies Stock Hit A New All-Time Low Todaymsn.com - April 1 at 3:51 PMDDC Appoints Vice President to Drive Operational Excellenceitnewsonline.com - March 30 at 6:23 PMSINTX Technologies Announces Proposed Public Offering of Common Stockglobenewswire.com - March 29 at 4:00 PMSINT Stock Earnings: SINTX Technologies Beats EPS, Beats Revenue for Q4 2023investorplace.com - March 28 at 7:02 AMSintx Technologies Prices Public Offering Of $1.3 Mln Of Sharesmarkets.businessinsider.com - March 25 at 1:22 PMWhy SINTX Technologies Stock Is Down 50%msn.com - March 25 at 1:22 PMWhy Is Sintx Technologies (SINT) Stock Down 31% Today?investorplace.com - March 25 at 9:05 AMSINTX Technologies Announces Pricing of $1.3 Million Public Offering of Common Stockglobenewswire.com - March 25 at 9:00 AMUS Stocks Edge Lower; FedEx Posts Upbeat Earningsmsn.com - March 23 at 3:15 AMWhy SINTX Technologies Is Trading Higher Todayaol.com - March 22 at 10:14 PMGold Moves Lower; Lululemon Shares Plummetmsn.com - March 22 at 5:14 PMDow Dips 200 Points; Nike Shares Fall After Q3 Resultsmarkets.businessinsider.com - March 22 at 5:14 PMSINTX Technologies Announces Intend To Offer And Sell Shares Of Common Stock; Stock Down 34%markets.businessinsider.com - March 22 at 5:14 PMWhy SINTX Technologies Stock Is Nosedivingmsn.com - March 22 at 5:14 PMSINTX Technologies Announces Proposed Public Offering of Common Stockglobenewswire.com - March 22 at 8:30 AMSintx Technologies (SINT) Price Target Increased by 42.86% to 10.20msn.com - February 24 at 2:14 PMTop 4 Health Care Stocks That Are Preparing To Pump This Month - ProSomnus (NASDAQ:OSA), GRI Bio (NASDAQ:GRI)benzinga.com - February 23 at 7:50 AMSINTX TECHNOLOGIES ENTERS INTO A SECOND LONG TERM SUPPLY AGREEMENT FOR THE AEROSPACE MARKETfinance.yahoo.com - February 21 at 3:58 PMSINTX TECHNOLOGIES ENTERS INTO A SECOND LONG TERM SUPPLY AGREEMENT FOR THE AEROSPACE MARKETglobenewswire.com - February 21 at 9:00 AMSINTX Technologies: Other Eventscbonds.com - February 16 at 10:37 AMSINTX Technologies subsidiary enters R&D agreement with the U.S. Army DEVCOM ARL for ceramic additive manufacturingtctmagazine.com - February 7 at 10:57 AMSintx Technologies just downgraded at Maxim, here's whyrealmoney.thestreet.com - February 5 at 5:59 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCellect BiotechnologyNASDAQ:APOPCellect Biotechnology Ltd. engages in the provision of regenerative medicine. Its activities include development of regenerative medicine through the development of products facilitating immune stem cell selection. The company also develops innovative technology, which allows the default stem cells by dramatically reducing of complications existing in conventional selection methods. The company was founded by Kasbian Nuriel Chirich, Shai Yarkoni, and Nadir Askenasy on August 4, 1986 and is headquartered in Kfar Saba, Israel.AvingerNASDAQ:AVGRAvinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. Its lumivascular products comprise Lightbox imaging consoles; the Ocelot and Tigereye family of devices, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. The company is also developing IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. The company was incorporated in 2007 and is based in Redwood City, California.InVivo TherapeuticsNASDAQ:NVIVInVivo Therapeutics Holdings Corp. operates as a research and clinical-stage biomaterials and biotechnology company in the United States. The company engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant comprise of biocompatible and bioresorbable polymers, which includes Poly lactic-co-glycolic acid, a polymer which is widely used in resorbable sutures and provides the biocompatible support for Neuro-Spinal Scaffold implant; and Poly-L-Lysine, a positively charged polymer used to coat surfaces to promote cellular attachment. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts. On February 1, 2024, InVivo Therapeutics Holdings Corp. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. It is in joint administration with InVivo Therapeutics Corporation.Sintx TechnologiesNASDAQ:SINTSintx Technologies, Inc., an advanced materials company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, industrial, and antipathogenic applications in the United States. It provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials and polyetherketoneketone. The company was formerly known as Amedica Corporation. Sintx Technologies, Inc. was incorporated in 1996 and is headquartered in Salt Lake City, Utah. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.